Safety and Dose Study of GRN163L Administered to Patients With Refractory or Relapsed Solid Tumor Malignancies

Exclusion Criteria

• •Pregnant or lactating women
• •Primary central nervous system(CNS) malignancy or active CNS metastases
• •Hematologic malignancy
• •Chemotherapy within 4 weeks prior to study
• •Mitomycin C, nitrosoureas within 6 weeks prior to study
• •High dose chemotherapy with stem cell support within 6 months prior to study
• •Signal transduction inhibitors, monoclonal antibodies, etc. within 4 weeks prior to study
• •Systemic hormonal therapy within 4 weeks prior to study
• •Anticoagulant therapy, antiplatelet therapy within 2 weeks prior to study
• •Radiotherapy within 4 weeks prior to study
• •Significant cardiovascular disease
• •Serious/active infection
• •Major surgical procedures within 2 weeks